The Phase III MATTERHORN trial demonstrated that Imfinzi (durvalumab) plus FLOT chemotherapy significantly improved event-free survival in resectable gastric and gastroesophageal junction cancers. The ...

Today, we are hosting Dr. Raza Bokhari, CEO at Medicus Pharma, to explore a breakthrough innovation in skin cancer treatment—SkinJect, a novel microneedle patch designed to eradicate cancerous cells ...

The US FDA has approved Tislelizumab (Tevimbra) plus platinum-based chemotherapy as a first-line treatment for adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) ...

A durvalumab (Imfinzi)-based perioperative regimen has been recommended by the EMA Committee for the treatment of adults with resectable non-small cell lung cancer. The recommendation is based on ...

The European Medicines Agency (EMA) committee (CHMP) has recommended approving trastuzumab deruxtecan (Enhertu), a HER2-directed antibody-drug conjugate for certain patients with metastatic breast ...

KEYTRUDA® (pembrolizumab) plus standard care for resectable locally advanced head and neck squamous cell carcinoma receives FDA priority review based on KEYNOTE-689 results. The trial showed improved ...

The early findings from the SERENA-6 trial indicate that oral SERD camizestrant provides a “highly statistically significant and clinically meaningful” improvement in progression-free survival for ...

Francis Medical, a medical device company developing water vapor ablation therapy for the treatment of prostate, kidney, and bladder cancer, announced the completion of patient enrollment and initial ...

The treatment landscape for hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (mBC) has evolved significantly, with CDK4/6 inhibitors in combination with endocrine therapy ...

In this exclusive interview with Dr. Maria de Miguel, Medical Oncologist and Clinical Investigator at START Madrid, we explore the transformative potential of Antibody-Drug Conjugates (ADCs) in ...

The CheckMate -816 trial shows nivolumab (Opdivo) plus platinum-doublet chemotherapy significantly improves overall survival in resectable non-small cell lung cancer. This combination, used ...

Artificial intelligence (AI) is evolving fast and life sciences is feeling the impact. In 2025, its role will expand even further, driving efficiencies and accelerating discoveries. The industry has ...